URGENT: This Altcoin Opportunity Won’t Wait – Act Now

All of our key indicators are flashing the same signal: an altcoin season is fast approaching. And if you know anything about crypto, you know that altcoin seasons are where some of the biggest gains happen.

Justin Burgess Biography and Net Worth

Insider of Dynavax Technologies

Justin Burgess is the Principal Accounting Officer & Controller at Dynavax Technologies.

What is Justin Burgess' net worth?: The estimated net worth of Justin Burgess is at least $49,022.88 as of May 17th, 2022. Mr. Burgess owns 3,854 shares of Dynavax Technologies stock worth more than $49,023 as of December 22nd. This net worth estimate does not reflect any other investments that Mr. Burgess may own. Learn More about Justin Burgess' net worth.
How do I contact Justin Burgess?: The corporate mailing address for Mr. Burgess and other Dynavax Technologies executives is 2100 Powell Street Suite 900, Emeryville CA, 94608. Dynavax Technologies can also be reached via phone at (510) 848-5100 and via email at [email protected]. Learn More on Justin Burgess' contact information.
Has Justin Burgess been buying or selling shares of Dynavax Technologies?: Justin Burgess has not been actively trading shares of Dynavax Technologies during the last quarter. Most recently, Justin Burgess sold 20,526 shares of the business's stock in a transaction on Friday, March 1st. The shares were sold at an average price of $12.78, for a transaction totalling $262,322.28. Learn More on Justin Burgess' trading history.
Who are Dynavax Technologies' active insiders?: Dynavax Technologies' insider roster includes Justin Burgess (Insider), Andrew Hack (Director), Robert Janssen (SVP), Kelly MacDonald (Sr. VP & CFO ), David Novack (COO), and Ryan Spencer (CEO). Learn More on Dynavax Technologies' active insiders.
Are insiders buying or selling shares of Dynavax Technologies?: In the last year, insiders at the biopharmaceutical company sold shares 4 times. They sold a total of 34,641 shares worth more than $457,999.23. The most recent insider tranaction occured on May, 31st when Director Francis Cano sold 3,615 shares worth more than $43,126.95. Insiders at Dynavax Technologies own 3.0% of the company. Learn More about insider trades at Dynavax Technologies.
Information on this page was last updated on 5/31/2024.

Justin Burgess Insider Trading History at Dynavax Technologies

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
3/1/2024	Sell	20,526	$12.78	$262,322.28
8/7/2023	Sell	8,061	$14.54	$117,206.94
2/27/2023	Sell	22,371	$10.38	$232,210.98
5/17/2022	Sell	6,000	$10.00	$60,000.00	3,854
3/3/2022	Sell	21,490	$10.58	$227,364.20
8/24/2021	Sell	5,768	$15.00	$86,520.00	9,489
3/1/2021	Sell	2,958	$8.88	$26,267.04	1,221

Justin Burgess Buying and Selling Activity at Dynavax Technologies

Dynavax Technologies Company Overview

Dynavax Technologies Corporation, a commercial stage biopharmaceutical company, focuses on developing and commercializing vaccines in the United States. It markets HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of hepatitis B virus in age 18 years and older in the United States and Europe. The company also manufactures and sells CpG 1018, the adjuvant used in HEPLISAV-B. Dynavax Technologies Corporation has a collaboration agreement with Valneva Scotland Limited; Zhejiang Clover Biopharmaceuticals, Inc.; Clover Biopharmaceuticals (Hong Kong) Co., Limited; Biological E. Limited; PT Bio Farma; Medigen Vaccine Biologics; and Serum Institute of India Pvt. Ltd. The company was formerly known as Double Helix Corporation and changed its name to Dynavax Technologies Corporation in September 1996. The company was incorporated in 1996 and is headquartered in Emeryville, California.

Today's Range

Now: $12.72

$12.68

$12.95

50 Day Range

MA: $12.24

$10.46

$13.66

2 Week Range

Now: $12.72

$9.74

$15.01

Volume

4,031,312 shs

Average Volume

2,119,194 shs

Market Capitalization

$1.67 billion

P/E Ratio

97.85

Dividend Yield

N/A

Beta

1.33